Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Armata Pharmaceuticals, Inc. (APHB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update"
08/03/2023 ARS Form ARS - Annual Report to Security Holders:
08/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/03/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/24/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
07/19/2023 8-K Quarterly results
07/19/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/11/2023 SC 13D/A Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC.
07/11/2023 8-K Resignation/termination of a director
Docs: "CREDIT AND SECURITY AGREEMENT Credit and Security Agreement, dated as of July 10, 2023, by and among Armata Pharmaceuticals, Inc., a Washington corporation , each Subsidiary of the Borrower listed as a “Guarantor” on the signature pages hereto , each a “ Guarantor ” and collectively, the “ Guarantors ”) and Innoviva Strategic Opportunities LLC, a Delaware limited liability company, or an affiliate thereof, as the lender . In consideration of the premises and the covenants and agreements contained herein, the parties hereto agree as follows: ARTICLE I DEFINITIONS; CERTAIN TERMS Section 1.01.     Definitions . As used in this Agreement, the following terms shall have the respective meanings indicated below:",
"FIRST AMENDMENT TO SECURED CONVERTIBLE CREDIT AND SECURITY AGREEMENT",
"Amendment No. 1 to THE Second AMENDED AND RESTATED voting agreement",
"Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 3 Averill Julianne (CFO) has filed a Form 3 on Armata Pharmaceuticals, Inc.
05/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/06/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/28/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
03/16/2023 8-K Quarterly results
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis",
"NYSE American: ARMP CONFIDENTIAL 2 Forward Looking Statements This"
02/13/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/07/2023 3 Butler Erin (Vice President,Finance & Admin) has filed a Form 3 on Armata Pharmaceuticals, Inc.
01/12/2023 4 Innoviva, Inc. (10% Owner) has filed a Form 4 on Armata Pharmaceuticals, Inc.
Txns: Bought options to buy @ $1.52, valued at $0
01/10/2023 SC 13D/A Innoviva, Inc. reports a 85.3% stake in ARMATA PHARMACEUTICALS, INC.
01/10/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Secured Convertible Credit and Security Agreement Dated as of January 10, 2023 by and among ARMATA PHARMACEUTICALS, INC., as the Borrower, EACH SUBSIDIARY OF THE BORROWER HERETO FROM TIME TO TIME, as Guarantors, and INNOVIVA STRATEGIC OPPORTUNITIES LLC, as the Lender",
"Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC"
12/19/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/09/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/17/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/20/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
08/11/2022 8-K Quarterly results
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/01/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/31/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/13/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy